WO1994016720A1 - COMPOSITIONS CONTENANT UN FACTEUR DE CROISSANCE TRANSFORMANT β STABILISE AU MOYEN DE GLYCOSAMINOGLYCANNES - Google Patents

COMPOSITIONS CONTENANT UN FACTEUR DE CROISSANCE TRANSFORMANT β STABILISE AU MOYEN DE GLYCOSAMINOGLYCANNES Download PDF

Info

Publication number
WO1994016720A1
WO1994016720A1 PCT/US1994/000490 US9400490W WO9416720A1 WO 1994016720 A1 WO1994016720 A1 WO 1994016720A1 US 9400490 W US9400490 W US 9400490W WO 9416720 A1 WO9416720 A1 WO 9416720A1
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
heparin
growth factor
activity
transforming growth
Prior art date
Application number
PCT/US1994/000490
Other languages
English (en)
Inventor
George Ksander
Ramon A. Burns
Veronica S. De Guzman
Edwin S. Kamemoto
Julie Pon
Ranga Nathan
Audrey A. Chow
Original Assignee
Celtrix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals, Inc. filed Critical Celtrix Pharmaceuticals, Inc.
Priority to AU60280/94A priority Critical patent/AU6028094A/en
Publication of WO1994016720A1 publication Critical patent/WO1994016720A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

L'invention concerne un procédé de stabilisation de l'activité d'un facteur de croissance transformant β par l'addition d'une dose suffisante d'héparine au facteur de croissance transformant β.
PCT/US1994/000490 1993-01-26 1994-01-21 COMPOSITIONS CONTENANT UN FACTEUR DE CROISSANCE TRANSFORMANT β STABILISE AU MOYEN DE GLYCOSAMINOGLYCANNES WO1994016720A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60280/94A AU6028094A (en) 1993-01-26 1994-01-21 Compositions containing transforming growth factor beta stabilized by glycosaminoglycans

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1148493A 1993-01-26 1993-01-26
US08/011,484 1993-01-26
US14414093A 1993-10-27 1993-10-27
US08/144,140 1993-10-27

Publications (1)

Publication Number Publication Date
WO1994016720A1 true WO1994016720A1 (fr) 1994-08-04

Family

ID=26682449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/000490 WO1994016720A1 (fr) 1993-01-26 1994-01-21 COMPOSITIONS CONTENANT UN FACTEUR DE CROISSANCE TRANSFORMANT β STABILISE AU MOYEN DE GLYCOSAMINOGLYCANNES

Country Status (2)

Country Link
AU (1) AU6028094A (fr)
WO (1) WO1994016720A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732105A2 (fr) * 1995-03-16 1996-09-18 Collagen Corporation Matrices de collagène à liaison d'affinité pour la délivrance de agents bioactifs
WO1998051780A2 (fr) * 1997-05-12 1998-11-19 Celtrix Pharmaceuticals, Inc. Methodes d'augmentation de rendements de proteines recombinees
US6649168B2 (en) 1999-03-17 2003-11-18 Novartis Ag Pharmaceutical compositions comprising TGF-beta

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
WO1992002247A1 (fr) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Methode de traitement des blessures endotheliales corneennes
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
EP0516901A1 (fr) * 1991-06-06 1992-12-09 Richard L. Lindstrom Solution médicale exempte de sérum; méthode et appareillage correspondant
EP0526756A1 (fr) * 1991-07-10 1993-02-10 C.R. Bard, Inc. Composition pour revitaliser le tissu cicatrisé

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
WO1992002247A1 (fr) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Methode de traitement des blessures endotheliales corneennes
EP0516901A1 (fr) * 1991-06-06 1992-12-09 Richard L. Lindstrom Solution médicale exempte de sérum; méthode et appareillage correspondant
EP0526756A1 (fr) * 1991-07-10 1993-02-10 C.R. Bard, Inc. Composition pour revitaliser le tissu cicatrisé

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732105A2 (fr) * 1995-03-16 1996-09-18 Collagen Corporation Matrices de collagène à liaison d'affinité pour la délivrance de agents bioactifs
EP0732105A3 (fr) * 1995-03-16 1999-02-24 Collagen Corporation Matrices de collagène à liaison d'affinité pour la délivrance de agents bioactifs
WO1998051780A2 (fr) * 1997-05-12 1998-11-19 Celtrix Pharmaceuticals, Inc. Methodes d'augmentation de rendements de proteines recombinees
WO1998051780A3 (fr) * 1997-05-12 1999-03-25 Celtrix Pharma Methodes d'augmentation de rendements de proteines recombinees
US5914390A (en) * 1997-05-12 1999-06-22 Celtrix Pharmaceuticals, Inc. Methods for increasing yields of recombinant proteins
US6649168B2 (en) 1999-03-17 2003-11-18 Novartis Ag Pharmaceutical compositions comprising TGF-beta

Also Published As

Publication number Publication date
AU6028094A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
EP0732105B1 (fr) Matrices de collagène à liaison d'affinité pour la délivrance de agents bioactifs
Schönherr et al. Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells.
Lyon et al. The interaction of the transforming growth factor-βs with heparin/heparan sulfate is isoform-specific
Morales et al. Transforming growth factor-β in calf articular cartilage organ cultures: synthesis and distribution
EP0830138B1 (fr) Utilisation d'analogues de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse
US5217954A (en) Formulations for stabilizing fibroblast growth factor
CA1294546C (fr) Composition cicatrisante contenant du collagene
Pfeilschifter et al. Transforming growth factor beta inhibits bone resorption in fetal rat long bone cultures.
US5130418A (en) Method to stabilize basic fibroblast growth factor
EP0394418B1 (fr) Facteurs osteogeniques
Massagué Transforming growth factor-beta modulates the high-affinity receptors for epidermal growth factor and transforming growth factor-alpha.
US4785079A (en) Isolation of fibroblast growth factor
Choi et al. IL-6 induces hepatic inflammation and collagen synthesis in vivo
EP0881908A1 (fr) Utilisation des facteurs de croissance de fibroblaste pour stimuler la croissance osseuse
Böhlen et al. HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function
JPH06505983A (ja) 創傷治癒の促進方法および促進薬
Wang et al. Characterization, stability, and formulations of basic fibroblast growth factor
Kimura et al. Schwannoma-derived growth factor promotes the neuronal differentiation and survival of PC12 cells.
Jennings et al. Heterogeneity of latent transforming growth factor-β isolated from bone matrix proteins
JP2002536016A (ja) ヘパリン結合能の亢進したポリペプチド変異体
US4902782A (en) Isolation of fibroblast growth factor
Du et al. Novel expression of the tyrosine hydroxylase gene requires both acidic fibroblast growth factor and an activator
WO1994016720A1 (fr) COMPOSITIONS CONTENANT UN FACTEUR DE CROISSANCE TRANSFORMANT β STABILISE AU MOYEN DE GLYCOSAMINOGLYCANNES
EP0680334B1 (fr) Traitement d'ulceres gastro-intestinaux avec des morphogenes
Neame et al. Small leucine-rich proteoglycans

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase